Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.69 |
| ▸ | RAB9A | P51151 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.64 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.63 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.61 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21588673 | 0.92 | HDAC6 (0.67) | NPC1RAB9AKMT2ANR1H4LMNA | |
| SCHEMBL25721410 | 0.92 | HDAC6 (0.67) | NPC1RAB9AKMT2ANR1H4LMNA | |
| SCHEMBL12652028 | 0.89 | RAB9A (0.68) | NPC1RAB9AKMT2ANR1H4LMNA | |
| SCHEMBL7295519 | 0.86 | NPC1 (0.66) | NPC1RAB9AKMT2ANR1H4LMNA | |
| SCHEMBL2350394 | 0.86 | ALDH1A1 (0.59) | NPC1RAB9AKMT2ANR1H4LMNA | |
| SCHEMBL823156 | 0.84 | RAB9A (0.75) | NPC1RAB9AKMT2AMAPTTDP1 | |
| SCHEMBL7303163 | 0.84 | HDAC3 (0.86) | NPC1RAB9AKMT2ANR1H4LMNA | |
| SCHEMBL7295360 | 0.84 | NR1H4 (0.60) | NPC1RAB9AKMT2ANR1H4LMNA | |
| SCHEMBL15652616 | 0.84 | NPC1 (0.61) | NPC1RAB9AKMT2ANR1H4LMNA | |
| SCHEMBL7295404 | 0.84 | NR1H4 (0.67) | NPC1RAB9AKMT2ANR1H4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476430-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110124640-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-26 | — | — | US | disclosed |
| WO-2010011837-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-28 | — | — | WO | disclosed |
| EP-0358118-B1 | Phenylamides - process for their preparation as well as a drug containing those compounds | BOEHRINGER MANNHEIM GMBH (DE) | 1994-03-16 | — | — | EP | disclosed |
| US-5135949-A | Anticoagulants | BOEHRINGER MANNHEIM GMBH (DE) | 1992-08-04 | — | — | US | disclosed |
| EP-0358118-A1 | Phenylamides - process for their preparation as well as a drug containing those compounds | Roche Diagnostics GmbH (DE) | 1990-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124640-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BTK, LYN, ABL1 | NPC1 4412/4885RAB9A 744/4885KMT2A 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.